Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer

RABL3基因突变会改变KRAS蛋白的异戊二烯化修饰,并与遗传性胰腺癌相关。

阅读:3
作者:Sahar Nissim ,Ignaty Leshchiner ,Joseph D Mancias ,Matthew B Greenblatt ,Ophélia Maertens ,Christopher A Cassa ,Jill A Rosenfeld ,Andrew G Cox ,John Hedgepeth ,Julia I Wucherpfennig ,Andrew J Kim ,Jake E Henderson ,Patrick Gonyo ,Anthony Brandt ,Ellen Lorimer ,Bethany Unger ,Jeremy W Prokop ,Jerry R Heidel ,Xiao-Xu Wang ,Chinedu I Ukaegbu ,Benjamin C Jennings ,Joao A Paulo ,Sebastian Gableske ,Carol A Fierke ,Gad Getz ,Shamil R Sunyaev ,J Wade Harper ,Karen Cichowski ,Alec C Kimmelman ,Yariv Houvras ,Sapna Syngal ,Carol Williams ,Wolfram Goessling

Abstract

Pancreatic ductal adenocarcinoma is an aggressive cancer with limited treatment options1. Approximately 10% of cases exhibit familial predisposition, but causative genes are not known in most families2. We perform whole-genome sequence analysis in a family with multiple cases of pancreatic ductal adenocarcinoma and identify a germline truncating mutation in the member of the RAS oncogene family-like 3 (RABL3) gene. Heterozygous rabl3 mutant zebrafish show increased susceptibility to cancer formation. Transcriptomic and mass spectrometry approaches implicate RABL3 in RAS pathway regulation and identify an interaction with RAP1GDS1 (SmgGDS), a chaperone regulating prenylation of RAS GTPases3. Indeed, the truncated mutant RABL3 protein accelerates KRAS prenylation and requires RAS proteins to promote cell proliferation. Finally, evidence in patient cohorts with developmental disorders implicates germline RABL3 mutations in RASopathy syndromes. Our studies identify RABL3 mutations as a target for genetic testing in cancer families and uncover a mechanism for dysregulated RAS activity in development and cancer.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。